Cancer Therapeutics Cooperative Research Centre

Cancer Therapeutics CRC (CTx), now operating as Canthera Therapeutics, is an Australian drug discovery and development organization focused on translating novel cancer research into clinical candidates. Established through the Australian Government's Cooperative Research Centres Program, the organization operates a collaborative model involving leading academic institutes and commercial partners. CTx specializes in small molecule discovery, particularly targeting epigenetic regulators and protein-protein interactions. The company has successfully licensed major programs to global pharmaceutical leaders, including a PRMT5 inhibitor to MSD and a KAT6 inhibitor to Pfizer. These partnerships have progressed assets into clinical trials, demonstrating the effectiveness of the CTx model in translating Australian science into global clinical candidates. The company continues to advance a pipeline of early-stage programs targeting various oncogenic drivers.